When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy
- 18 May 2015
- journal article
- Published by Wiley in Transfusion
- Vol. 55 (6pt2), 1555-1562
- https://doi.org/10.1111/trf.13150
Abstract
Monoclonal antibodies (MoAbs) are increasingly integrated in the standard of care. The notion that therapeutic MoAbs can interfere with clinical laboratory tests is an emerging concern that requires immediate recognition and the development of appropriate solutions. Here, we describe that treatment of multiple myeloma patients with daratumumab, a novel anti-CD38 MoAb, resulted in false-positive indirect antiglobulin tests (IATs) for all patients for 2 to 6 months after infusion. This precluded the correct identification of irregular blood group antibodies for patients requiring blood transfusion.The IAT was performed using three- and 11-donor-cell panels. Interference of daratumumab and three other anti-CD38 MoAbs was studied using fresh-frozen plasma spiked with different MoAb concentrations. Additionally it was tested whether two potentially neutralizing agents, anti-idiotype antibody and recombinant soluble CD38 (sCD38) extracellular domain, were able to inhibit the interference.The CD38 MoAbs caused agglutination in the IAT in a dose-dependent manner. Addition of an excess of anti-idiotype antibodies or sCD38 protein to the test abrogated CD38 MoAb interference and successfully restored irregular antibody screening and identification.CD38 MoAb therapy causes false-positive results in the IAT. The reliability of the test could be restored by adding a neutralizing agent against the CD38 MoAb to the patient's plasma. This study emphasizes that during drug development, targeted therapeutics should be investigated for potential interference with laboratory tests. Clinical laboratories should be informed when patients receive MoAb treatments and matched laboratory tests to prevent interference should be employed.This publication has 12 references indexed in Scilit:
- A simple, robust and highly efficient transient expression system for producing antibodiesMethods, 2014
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapiesBlood Cancer Journal, 2011
- Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresisBritish Journal of Haematology, 2011
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis TestsClinical Chemistry, 2010
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Novel human antibody therapeutics: The age of the UmabsBiotechnology Journal, 2008
- Erythrocyte CD38 as a prognostic marker in cancerHematology, 2007
- Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of ActionCancer Research, 2006
- Pathophysiology of Immune Hemolytic AnemiaAnnals of Internal Medicine, 1977